{"id":"W4389455899","doi":"10.1182/blood-2023-191921","title":"Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Ibrutinib; Venetoclax; Mantle cell lymphoma; Internal medicine; Tumor lysis syndrome; Oncology; Bendamustine; Ven; Phases of clinical research; Neutropenia; Febrile neutropenia; Clinical endpoint; Tolerability; Rituximab; Clinical trial; Lymphoma; Chronic lymphocytic leukemia; Adverse effect; Leukemia; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001343274,0.0003304444,0.001241223,0.0003847491,0.0001225135,0.00005063712,0.0003401193,0.0001109537,0.00004353293],"category_scores_gemma":[0.0004214212,0.0001813745,0.0001731408,0.002365369,0.0002302816,0.00008963367,0.0001631404,0.0002731661,0.00009026191],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002543412,"about_ca_system_score_gemma":0.003731421,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00248512,"about_ca_topic_score_gemma":0.0003637327,"domain_scores_codex":[0.9960623,0.0005818535,0.0007357727,0.0007172656,0.001334756,0.0005680348],"domain_scores_gemma":[0.9957694,0.002239888,0.0002798487,0.001337279,0.0001787722,0.0001947758],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8084085,0.03367038,0.138483,0.0001212504,0.007971335,0.001867623,0.007279585,0.0003651883,0.0000711559,0.000003917072,0.0009168464,0.0008412114],"study_design_scores_gemma":[0.8398581,0.002508547,0.150175,0.0001123609,0.003999199,0.000002160046,0.0005452561,0.002334266,0.0002055119,0.000006149209,0.00004777446,0.0002056499],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948361,0.0001108607,0.000005959561,0.0000979289,0.00004361119,0.00366078,0.0001310387,0.0001210862,0.0009926332],"genre_scores_gemma":[0.9975504,0.00003439865,0.0001048725,0.0001062596,0.00006285217,0.00025494,0.001262455,0.00006311208,0.0005607234],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0314496,"threshold_uncertainty_score":0.7396238,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01087221513785876,"score_gpt":0.2567697260689992,"score_spread":0.2458975109311404,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}